Related Experiment Video
Updated: Aug 28, 2025

Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
IS HOMEOSTASIS MODEL ASSESSMENT FOR INSULIN RESISTANCE >2.5 A DISTINGUISHED CRITERIA FOR METABOLIC
Bárbara Ferreira de Mello Barreto1, Giovana Rita Punaro2, Maria Cristina Elias1
1Universidade Federal de São Paulo, Departamento de Medicina-Gastroenterologia, São Paulo, SP, Brasil.
Homeostasis model assessment-insulin resistance (HOMA-IR) >2.5 identifies patients with metabolic dysfunction-associated fatty liver disease (MAFLD) who have distinct clinical and metabolic characteristics. This marker indicates a greater potential for disease progression in non-alcoholic fatty liver disease (NAFLD).
Area of Science:
- Hepatology
- Metabolic Syndrome
- Endocrinology
Background:
- Insulin resistance (IR) is a key factor in non-alcoholic fatty liver disease (NAFLD) pathogenesis.
- Metabolic dysfunction-associated fatty liver disease (MAFLD) is a recently characterized condition.
- Homeostasis model assessment-insulin resistance (HOMA-IR) is a proposed diagnostic criterion for MAFLD.
Purpose of the Study:
- To evaluate the association of HOMA-IR >2.5 with clinical, metabolic, biochemical, and histological data.
- To analyze these associations in non-diabetic patients diagnosed with NAFLD via liver biopsy.
Main Methods:
- Retrospective, cross-sectional study of 174 non-diabetic NAFLD patients.
- Classification of body mass index (BMI) and metabolic syndrome (MS) using established criteria.
- Automated methods for biochemical tests and immunofluorometric assay for insulinemia.
Main Results:
- Patients with HOMA-IR >2.5 showed a higher prevalence of MS, elevated liver enzymes, and serum ferritin.
- These patients also had a higher prevalence of non-alcoholic steatohepatitis (NASH) and advanced liver fibrosis.
- Multivariate analysis identified MS, hyperferritinemia, and NASH as independent factors associated with altered HOMA-IR.
Conclusions:
- HOMA-IR >2.5 identifies NAFLD patients with specific clinical and metabolic profiles.
- This marker is associated with a higher potential for disease progression.
- HOMA-IR >2.5 is validated as a parameter for identifying patients with MAFLD.
More Related Videos
Related Concept Videos
Diabetes: Symptoms, Diagnosis, and Complications
Overview of Lipid Metabolism
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Carbohydrate Metabolism
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Obesity
Ultrasound II: Endoscopic Ultrasound and FibroScan
Endoscopic Ultrasound (EUS):
Diabetes Mellitus: Type 2 and Gestational

